Table 2. Pulmonary function test (PFT) results and clinical and radiological improvement in patients with familial and sporadic sarcoidosis.
| Variable | Familial | Sporadic | P value | N familial | N sporadic |
|---|---|---|---|---|---|
| FVC | |||||
| Diagnosis (%) | 91.5±15.6 | 90.8±15.8 | 0.744 | 54 | 755 |
| Last follow-up (%) | 93.0±16.6 | 90.5±16.3 | 0.335 | 45 | 648 |
| Diagnosis (L) | 3.9±1.1 | 3.9±1.2 | 0.744 | 53 | 757 |
| Last follow-up (L) | 3.9±1.2 | 3.8±1.2 | 0.534 | 45 | 651 |
| Δ FVC (L) | 0.08±0.4 | −0.02±0.4 | 0.107 | 39 | 547 |
| FEV1 | |||||
| Diagnosis (%) | 91.9±14.5 | 89.0±17.2 | 0.159 | 54 | 760 |
| Last follow-up (%) | 93.2±15.2 | 88.9±17.6 | 0.109 | 46 | 653 |
| Diagnosis (L) | 3.2±1.0 | 3.1±1.0 | 0.744 | 54 | 760 |
| Last follow-up (L) | 3.1±1.0 | 3.0±1.0 | 0.345 | 45 | 653 |
| Δ FEV1 (L) | −0.06±0.4 | −0.04±0.4 | 0.769 | 40 | 550 |
| FEV1%/FVC | |||||
| Diagnosis | 80.5±6.7 | 78.3±7.8 | 0.142 | 52 | 726 |
| Last follow-up | 78.8±7.1 | 76.8±9.0 | 0.069 | 56 | 786 |
| DLCO | |||||
| Diagnosis (%) | 90.5±16.8 | 86.9±16.4 | 0.358 | 46 | 690 |
| Last follow-up (%) | 85.3±14.5 | 84.5±17.2 | 0.877 | 36 | 579 |
| Δ DLCO (%) | −4.1±12.8 | −1.5±11.4 | 0.230 | 29 | 453 |
| Period between PFTs (y) | 2.9 (1.7–6.6) | 2.4 (1.6–4.0) | 0.105 | 40 | 560 |
| Clinical improvement | |||||
| Follow-up | 24 (39.3) | 386 (43.5) | 0.529 | 61 | 888 |
| Last follow-up | 33 (63.5) | 476 (61.3) | 0.761 | 52 | 776 |
| Radiological improvement | |||||
| Follow-up | 17 (31.5) | 359 (46.0) | 0.038 | 54 | 780 |
| Last follow-up | 26 (56.5) | 456 (65.2) | 0.231 | 46 | 699 |
The data are presented as the means±SDs (SD) and median (IQR).
DLCO, corrected diffusing capacity for carbon monoxide; FEV1, forced expiratory volume in 1 s; FVC, forced vital capacity; PFT, pulmonary function test.